ANGLE plc Delivers 31% Revenue Growth and Strengthens Ties with Major Pharma Partners in 2024

PUBLISHED: 28 May 2025 @ 18:07 | Comments (0) | More info about Fiona Craig

ANGLE plc (LSE:AGL) has reported a 31% rise in revenue for 2024, reflecting the success of its strategic pivot toward large pharmaceutical collaborations. Despite facing headwinds in product sales—due in part to evolving regulatory landscapes and constrained research funding—the company’s focus on securing high-value pharma contracts has positioned it for long-term growth and resilience.

In addition to streamlining its operations, ANGLE has inked several new agreements with major pharmaceutical firms, laying the groundwork for expanded use of its technologies in oncology drug development. The company also highlighted progress in next-generation sequencing (NGS) assays and its growing influence in cutting-edge cancer research.

Looking ahead, ANGLE anticipates modest revenue growth in 2025 but remains confident in converting current partnership discussions into significant business opportunities.

Company Overview: ANGLE plc

ANGLE plc is a leading innovator in the liquid biopsy space, specializing in circulating tumor cell (CTC) technologies that support cancer diagnostics, research, and drug development. With a focus on precision oncology, the company partners with top-tier pharmaceutical companies to accelerate the development of targeted therapies and improve clinical outcomes.

While current market sentiment remains cautious—with technical indicators pointing to a “Sell” signal—ANGLE’s strategic repositioning and advancements in cancer diagnostics offer a compelling outlook for future growth.

Average Daily Trading Volume: 1,093,524
Technical Sentiment: Sell
Current Market Capitalization: £33.86 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.